Dara-SVD vs. Dara-RVD

A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma

Arms / Cohorts

Experimental, Arm 1:Selinexor + Daratumumab + Velcade + Dexamethasone

Accepting patients

Active Comparator, Arm 2:Daratumumab + Lenalidomide + Velcade + Dexamethasone

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.